A Case of Severe Hypercalcemia after Treatment with Teriparatide for Osteoporosis.
10.11005/kjbm.2012.19.1.53
- Author:
Ja Won KOO
1
;
Jung Hoon LEE
;
Na Eun JANG
;
Hyuck KIM
;
Hwa Young SEOK
;
Ye Ri SO
;
A Ri SHIN
;
Joo Hee CHO
;
Sang Ho LEE
Author Information
1. Department of Nephrology, Kyung Hee University Hospital at Gangdong, Seoul, Korea. rulale@dreamwiz.com
- Publication Type:Case Report
- Keywords:
Hypercalcemia;
Osteoporosis;
Teriparatide
- MeSH:
Calcium;
Female;
Gait;
Humans;
Hypercalcemia;
Male;
Osteogenesis;
Osteoporosis;
Osteoporotic Fractures;
Parathyroid Hormone;
Teriparatide;
United States;
Vitamin D
- From:Korean Journal of Bone Metabolism
2012;19(1):53-58
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recombinant human parathyroid hormone 1-34 (rHPTH; 1-34, teriparatide) increases bone mass and increases osteoporotic fracture by stimulating new bone formation. It was approved in the United States for treatment of osteoporosis in men and women, and its effectiveness and safety was proved. Mild hypercalcemia was observed, but persistent and severe hypercalcemia was not observed in the studies of teriparatide. In this case, severe hypercalcemia was developed from patient having gait disturbance who was treated with vitamin D, calcium and teripartide for two months to treat osteoporosis after subtrochanteric fracture. Hypercalcemia was resolved with discontinuation of teriparatide. Severe hypercalcemia is not a common complication of teriparatide and monitoring of serum calcium level is routinely not recommended. But it is necessary to pay close attention to patients who were treated with teriparatide, especially in immobilized patients.
